Despite recent advances, chronic heart failure remains a significant and growing unmet medical need, reaching epidemic proportions carrying substantial morbidity, mortality, and costs. A safe and convenient therapeutic agent that produces sustained inotropic effects could ameliorate symptoms and improve functional capacity and quality of life. The authors discovered that small amounts of 2-deoxy-ATP (dATP) activate cardiac myosin leading to enhanced contractility in normal and failing heart muscle. Cardiac myosin activation triggers faster myosin cross-bridge cycling with greater force generation during each contraction. They describe the rationale and results of a translational medicine effort to increase dATP levels using a gene therapy strategy that up-regulates ribonucleotide reductase, the rate-limiting enzyme for dATP synthesis, selectively in cardiomyocytes. In small and large animal models of heart failure, a single dose of this gene therapy has led to sustained inotropic effects with no toxicity or safety concerns identified to date. Further animal studies are being conducted with the goal of testing this agent in patients with heart failure. 
through the adrenergic system or cyclic AMP has improved symptoms and exercise capacity by increasing ejection fraction, but the benefit of these drugs has been limited by long-term safety and tolerance issues and by the need for parenteral administration (1-3). Importantly, data from patients with cardiac resynchronization and left ventricular (LV) assist devices suggest chronic improvement of cardiac function may prevent or reverse the progression of HF (4, 5) . R1R2 is well characterized and consists of 2 subunits: the larger R1 subunit contains the catalytic site and 2 allosteric sites that can bind dATP, whereas the smaller R2 subunit contains the free radical generator. R1R2 is tightly allosterically regulated, with #5%
of the ATP pool present as dATP (18, 19) . However, because cardiomyocytes are nonreplicating cells, R1R2 expression is markedly down-regulated and cardiomyocyte dATP levels are <10% of those in other cells (20) . dATP concentration can be increased by overexpression of R1R2, the rate-limiting enzyme in its production, using gene therapy.
BB-R12 is a designed multicomponent gene therapy agent consisting of a recombinant serotype-6 adenoassociated viral vector (AAV6) carrying a genome containing a human cardiac troponin T regulatory cassette (hcTnT455) linked to a transgene encoding human sequences of both the large (R1) and small (R2) subunits of R1R2 (separated by a protein cleavage site) to overexpress the enzyme in myocardium.
Although BB-R12 is nominally a gene therapy, the therapeutic algorithm employed is novel. Rather than correcting a genetic or proteomic defect, increased dATP levels act as a locally produced inotropic small molecule treatment for the failing heart. In essence, BB-R12 creates a drug production and delivery system within the heart using gene therapy. Local, intracellular production of dATP may also lower the risk of off-target systemic side effects. On the basis of the initial insight that dATP is a more efficient energy source for muscle contraction, the gene therapy 
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BB-R12 Gene Therapy for Heart Failure approach of up-regulating myocardial R1R2 has progressed from testing in cardiomyocytes and myofibrils, to small animal HF models, and most recently to large animal HF models. The results of these published studies are summarized in the following text.
Further testing is underway with the goal of testing this therapy in patients with HF. Later studies showed dATP substitution for ATP in demembranated rat cardiac trabeculae resulted in increased isometric force at all levels of Ca 2þ activation. Cardiac muscle "stiffness" (an experimental measurement of cross-bridge binding) and force were sensitivity of force in cardiac muscle. In both cardiac and skeletal muscle, contractile kinetics were enhanced with dATP; however, increased maximal force production was only seen in cardiac muscle (24, 25) .
Addition of low levels of dATP to the ATP pool at physiological Ca 2þ levels resulted in significant increases in force development in rat cardiac muscle.
Briefly, demembranated rat cardiac trabeculae were This study demonstrated that even small amounts of cellular dATP added to ATP are sufficient to increase contractile force in cardiac tissue by increasing crossbridge recruitment (20) . These data, confirmed by the work of others, suggest that the analogy to a "fuel additive" is more appropriate than "higher-octane fuel" (26) (27) (28) . These studies were the first indicator of the therapeutic potential of dATP. showed a 13% increase in force production and a 44% increase in activation rate with dATP, with no effect on relaxation rates and no prolongation of systole. In agreement with rat cardiac tissue studies, increased force production, Ca 
dATP MECHANISM OF ACTION
The potential underlying chemomechanical mechanisms for improved contractility seen with dATP were studied using molecular modeling and confirmed with motility assays. A well-characterized myosin structure in the pre-powerstroke state was used as a starting structure for molecular dynamics simulations (32) , and atom-level differences in myosin structure and dynamics with dADP binding were evaluated.
Simulations showed that when dADP.Pi (the nucleotide form present for actin binding) is in the nucleotide binding pocket of myosin, the PHE129 that normally binds to O2 0 at the 2 position of the ribose Recently reported data from an independent group showed dATP increased myosin-actin sliding velocities by 40%, and increased ATPase activity, ADP release rates, and actin-binding affinities (34) .
Omecamtiv mecarbil also increases Ca 2þ sensitivity and force of contraction, but by contrast, through an increase in the probability of transition from weak to strong (force-producing) actin-myosin binding states (12, 35) . No increase in the kinetics of cross-bridge cycling has been reported, but it has been suggested that more myosin heads are recruited and have a prolonged interaction with actin. This has been measured as no change in þdP/dt or ÀdP/dt, and a prolongation of systole ( Figure 1C ).
TRANSLATIONAL MEDICINE CHALLENGE DEVELOPING A GENE-DELIVERY SYSTEM TO INCREASE dATP SPECIFICALLY IN CARDIAC TISSUE.
Chronic administration of dATP directly to the heart is not a feasible strategy to achieve long-term thera- 
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BB-R12 Gene Therapy for Heart Failure To reduce immune responses to the AV delivery system and achieve long-term expression of R1R2 in myocardium, AAV6 systems were developed that targeted cardiac tissue ( Table 1 Further translational development led to a single AAV6 vector system containing a transgene cassette expressing optimized human sequences of both R1 and R2 subunits separated by a protein cleavage site (P2A internal ribosome entry site peptide) under a single cardiac-specific promoter (hcTnT455) ( Table 1) . 
BB-R12 AS INOTROPIC THERAPY
Inotropic agents have been shown to be effective for both short-and long-term treatment of HF, but their utility has been limited primarily by safety concerns.
These inotropic agents work upstream of calcium signaling and myosin contractions via stimulation of the adrenergic system (dopamine, dobutamine, norepinephrine) or by inhibiting phosphodiesterase and cAMP production (milrinone, vesnarinone, enoximone) ( Figure 1A ) (3). Briefly, these safety problems are tachyarrhythmias and myocardial ischemia/hypotension due to the primary mechanisms of action (i.e., "on-mechanism" but off-target) (42) . The promise of new therapies targeting calcium-cycling or activating myosin is that these work downstream from the signaling mechanisms that can cause the side effects. This more targeted mechanism may yield a more acceptable benefit-risk profile. 
LIMITATIONS AND FUTURE DIRECTIONS

CONCLUSIONS
The observation that dATP activates cardiac myosin in healthy and failing cardiomyocytes has been 
